Fig. S2.

Clinical manifestations of CX3CR1^−/− EAE mice receiving ChAT⁺/ChAT⁻ NK cells intravenously. A total of 1 × 10⁶ ChAT⁺ or ChAT⁻ NK cells in 100 μL PBS was injected i.v. from 9 to 13 dpi. (A) The curves of clinical scores show diminished disease severity in the ChAT⁺ NK cell-injected group, whereas only limited effect was observed in the ChAT⁻ NK cell-injected group. (B) The cumulative clinical score indicates reduced severity of EAE after i.v. injection of ChAT⁺ NK cells. (C) ChAT⁺ NK cell injection significantly delayed disease onset. n = 6 per group. Mean ± SEM. *P < 0.05.